Research Advance of Urate-lowering Therapy on Kidney Protection

doi:10.12114/j.issn.1007-9572.2018.00.286

Abstract

Abstract: Patients with gout often have some complications，such as cardiovascular diseases，chronic kidney diseases，and metabolic syndrome.Some studies suggested that hyperuricemia and gout increased the risk of chronic kidney diseases.Therefore，it is important to research on the effect of urate-lowering therapy on chronic kidney disease.At present，the effect of urate-lowering therapy on chronic kidney disease is not yet clear.Some randomized controlled studies have found that allopurinol can slow down the deterioration of renal function.The current research on febuxostat is controversial and we are lack of high quality research of benzbromarone in treatment of chronic kidney diseases.In the future，more studies are still needed on kidney protection by urate-lowering therapy.

Key words: Gout, Urate-lowering therapy, Allopurinol, Febuxostat, Benzbromarone, Renal function

摘要： 痛风患者常出现并发症，如心血管系统疾病、肾功能不全和代谢综合征等。部分研究认为高尿酸血症和痛风会增加慢性肾脏病的风险。因此，降尿酸治疗对于慢性肾脏病的影响研究非常重要。目前，降尿酸治疗对慢性肾脏病的影响尚不明确，部分随机对照研究发现别嘌醇可以减缓肾功能的恶化，而非布司他的相关研究目前存在争议，并且缺乏苯溴马隆在慢性肾脏病方面的高质量研究。今后，仍需在降尿酸治疗的肾脏保护方面进行更多的研究。

关键词: 痛风, 降尿酸治疗, 别嘌醇, 非布司他, 苯溴马隆, 肾功能

XIN Lei,LIANG Jingjing,GAO Ying, et al. Research Advance of Urate-lowering Therapy on Kidney Protection　[J]. Chinese General Practice, 2019, 22(17): 2025-2029. DOI: 10.12114/j.issn.1007-9572.2018.00.286.
辛雷,梁菁菁,高颖等. 降尿酸治疗对肾脏保护作用的研究进展[J]. 中国全科医学, 2019, 22(17): 2025-2029. DOI: 10.12114/j.issn.1007-9572.2018.00.286.

References

［1］MCCARTY D J，HOLLANDER J L.Identification of urate crystals in gouty synovial fluid［J］．Ann Intern Med，1961，54（3）：452-460.
［2］中华医学会风湿病学分会.2016中国痛风诊疗指南［J］．中华内科杂志，2016，55（11）：892-899．DOI：10.3760/cma.j.issn.0578-1426.2016.11.019.　
Chinese Rheumatology Association.2016 China gout clinical practice guideline［J］．Chinese Journal of Internal Medicine，2016，55（11）：892-899．DOI：10.3760/cma.j.issn.0578-1426.2016.11.019.
［3］TAYLOR W J，FRANSEN J，JANSEN T L，et al．Study for updated gout classification criteria：identification of features to classify gout［J］．Arthritis Care Res（Hoboken），2015，67（9）：1304-1315．DOI：10.1002/acr.22585.
［4］KUO C F，GRAINGE M J，MALLEN C，et al．Comorbidities in patients with gout prior to and following diagnosis：case-control study［J］．Ann Rheum Dis，2016，75（1）：210-217．DOI：10.1136/annrheumdis-2014-206410.
［5］RICHETTE P，CLERSON P，PéRISSIN L，et al．Revisiting comorbidities in gout：a cluster analysis［J］．Ann Rheum Dis，2015，74（1）：142-147.
［6］HUGHES K，FLYNN T，DE ZOYSA J，et al．Mendelian randomization analysis associates increased serum urate，due to genetic variation in uric acid transporters，with improved renal function［J］．Kidney Int，2014，85（2）：344-351．DOI：10.1038/ki.2013.353.
［7］ISEKI K，IKEMIYA Y，INOUE T，et al．Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort［J］．Am J Kidney Dis，2004，44（4）：642-650.
［8］OBERMAYR R P，TEMML C，GUTJAHR G，et al．Elevated uric acid increases the risk for kidney disease［J］．J Am Soc Nephrol，2008，19（12）：2407-2413．DOI：10.1681/ASN.2008010080.
［9］LI L，YHEN C，ZHAO Y，et al．Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?：a systematic review and meta-analysis based on observational cohort studies［J］．BMC Nephrol，2014，15（1）：122．DOI：10.1186/1471-2369-15-122.
［10］KANG D H，NAKAGAWA T，FENG L，et al．A role for uric acid in the progression of renal disease［J］．J Am Soc Nephrol，2002，13（12）：2888-2897.
［11］SáNCHEZ-LOZADA L G，TAPIA E，SANTAMARíA J，et al．
Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats［J］．Kidney Int，2005，67（1）：237-247．DOI：10.1111/j.1523-1755.2005.00074.x.
［12］AYOUB I，ALMAANI S，BRODSKY S，et al．Revisiting medullary tophi：a link between uric acid and progressive chronic kidney disease?［J］．Clin Nephrol，2016，85（2）：109-113．DOI：10.5414/CN108663.
［13］MUGWAGWA A N，FISCHER R，ZAILAN I.HLA-B*5801：a genetic susceptibility to allopurinol-induced DRESS［J］．Med J Aust，2016，204（4）：159-160.
［14］SIU Y P，LEUNG K T，TONG M K，et al．Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level［J］．Am J Kidney Dis，2006，47（1）：51-59．DOI：10.1053/j.ajkd.2005.10.006.
［15］SATIRAPOJ B，WIRAJIT O，BURATA A，et al．Benefits of allopurinol treatment on blood pressure and renal function in patients with early stage of chronic kidney disease［J］．J Med Assoc Thai，2015，98（12）：1155-1161.
［16］KRISHNAMURTHY A，LAZARO D，STEFANOV D G，et al．The effect of allopurinol on renal function［J］．J Clin Rheumatol，2017，23（1）：1-5．DOI：10.1097/RHU.0000000000000480.
［17］MOMENI A，SHAHIDI S，SEIRAFIAN S，et al．Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients［J］．Iran J Kidney Dis，2010，4（2）：128-132.
［18］KAO M P，ANG D S，GANDY S J，et al．Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease［J］．J Am Soc Nephrol，2011，22（7）：1382-1389．DOI：10.1681/ASN.2010111185.
［19］HANDE K R，NOONE R M，STONE W J.Severe allopurinol toxicity.Description and guidelines for prevention in patients with renal insufficiency［J］．Am J Med，1984，76（1）：47-56.
［20］HALEVY S，GHISLAIN P D，MOCKENHAUPT M，et al．Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel［J］．J Am Acad Dermatol，2008，58（1）：25-32.
［21］RICHETTE P，DOHERTY M，PASCUAL E，et al．2016 updated EULAR evidence-based recommendations for the management of gout［J］．Ann Rheum Dis，2017，76（1）：29-42．DOI：10.1136/annrheumdis-2016-209707.
［22］GREWAL H K，MARTINEZ J R，ESPINOZA L R.Febuxostat：drug review and update［J］．Expert Opin Drug Metab Toxicol，2014，10（5）：747-758．DOI：10.1517/17425255.2014.904285.
［23］BECKER M A，SCHUMACHER H R，ESPINOZA L R，et al．The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout：the CONFIRMS trial［J］．Arthritis Res Ther，2010，12（2）：R63．DOI：10.1186/ar2978.
［24］HOSOYA T，OHNO I.A repeated oral administration study of febuxostat （TMX-67），a non-purine-selective inhibitor of xanthine oxidase，in patients with impaired renal function in Japan：pharmacokinetic and pharmacodynamic study［J］．J Clin Rheumatol，2011，17（4 Suppl 2）：S27-34．DOI：10.1097/RHU.0b013e31821d36f2.
［25］SIRCAR D，CHATTERJEE S，WAIKHOM R，et al．Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia：a 6-month，double-blind，randomized，placebo-controlled trial［J］．Am J Kidney Dis，2015，66（6）：945-950．DOI：10.1053/j.ajkd.2015.05.017.
［26］TANAKA K，NAKAYAMA M，KANNO M，et al．Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease：a parallel-group，randomized，controlled trial［J］．Clin Exp Nephrol，2015，19（6）：1044-1053．DOI：10.1007/s10157-015-1095-1.
［27］SAAG K G，WHELTON A，BECKER M A，et al．Impact of febuxostat on renal function in gout patients with moderate-to-severe renal impairment［J］．Arthritis Rheumatol，2016，68（8）：2035-2043．DOI：10.1002/art.39654.
［28］GRABOWSKI B A，KHOSRAVAN R，VERNILLET L，et al．Metabolism and excretion of［14C］ febuxostat，a novel nonpurine selective inhibitor of xanthine oxidase，in healthy male subjects［J］．J Clin Pharmacol，2011，51（2）：189-201．DOI：10.1177/0091270010365549.
［29］杨会军，李兆福，万春平，等．尿酸盐转运蛋白在原发性痛风及高尿酸血症中的研究进展［J］．中华中医药学刊，2013，31（9）：1891-1894.
YANG H J，LI Z F，WAN C P，et al．Research progress of urate transporter in primary gout and hyperuricemia［J］．Chinese Archives of Traditional Chinese Medicine，2013，31（9）：1891-1894.
［30］ZHANG W，DOHERTY M，BARDIN T，et al．EULAR evidence based recommendations for gout.Part Ⅱ：management.Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics （ESCISIT）［J］．Ann Rheum Dis，2006，65（10）：1312-1324.
［31］JORDAN K M，CAMERON J S，SNAITH M，et al．British Society for Rheumatology and British Health Professionals in rheumatology guideline for the management of gout［J］．Rheumatology（Oxford），2007，46（8）：1372-1374.
［32］FUJIMORI S，OOYAMA K，OOYAMA H，et al．Efficacy of benzbromarone in hyperuricemic patients associated with chronic kidney disease［J］．Nucleosides Nucleotides Nucleic Acids，2011，30（12）：1035-1038．DOI：10.1080/15257770.2011.622732.
［33］CHOU H W，CHIU H T，TSAI C W，et al．Comparative effectiveness of allopurinol，febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia：a 13-year inception cohort study［J］．Nephrol Dial Transplant，2018，33（9）：1620-1627．DOI：10.1093/ndt/gfx313.
［34］SAUTIN Y Y，NAKAGAWA T，ZHARIKOV S，et al．Adverse effects of the classic antioxidant uric acid in adipocytes：NADPH oxidase-mediated oxidative/nitrosative stress［J］．Am J Physiol Cell Physiol，2007，293（2）：C584-596．DOI：10.1152/ajpcell.00600.2006.
［35］KANG D H，HAN L，OUYANG X，et al．Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter［J］．Am J Nephrol，2005，25（5）：425-433．DOI：10.1159/000087713.
［36］KADOWAKI D，SAKAGUCHI S，MIYAMOTO Y，et al．Direct radical scavenging activity of benzbromarone provides beneficial antioxidant properties for hyperuricemia treatment［J］．Biol Pharm Bull，2015，38（3）：487-492．DOI：10.1248/bpb.b14-00514.
［37］梁德荣，徐楠，张辉明，等．苯溴马隆与磺丙舒治疗痛风的随机对照研究［J］．华西医学，1994，9（4）：405-408.
LIANG D R，XU N，ZHANG H M，et al．A randomized controlled study of benzbromarone and probenecid in the treatment of gout［J］．West China Medical Journal，1994，9（4）：405-408.
［38］WAGAYAMA H，SHIRAKI K，SUGIMOTO K，et al．Fatal fulminant hepatic failure associated with benzbromarone［J］．J Hepatol，2000，32（5）：874.
［39］SUZUKI T，SUZUKI T，KIMURA M，et al．A case of fulminant hepatitis，possibly caused by benzbromarone［J］．Nihon Shokakibyo Gakkai Zasshi，2001，98（4）：421-425.
［40］ARAI M，YOKOSUKA O，FUJIWARA K，et al．Fulminant hepatic failure associated with benzbromarone treatment：a case report［J］．J Gastroenterol Hepatol，2002，17（5）：625-626.
［41］LEE M H，GRAHAM G G，WILLIAMS K M，et al．A benefit-risk assessment of benzbromarone in the treatment of gout［J］．Drug Saf，2008，31（8）：643-665.
［42］KEENAN R T，O'BRIEN W R，LEE K H，et al．Prevalence of contraindications and prescription of pharmacologic therapies for gout［J］．Am J Med，2011，124（2）：155-163．DOI：10.1016/j.amjmed.2010.09.012.
［43］HUI M，CARR A，CAMERON S，et al．The British Society for Rheumatology Guideline for the management of gout［J］．Rheumatology（Oxford），2017，56（7）：1246．DOI：10.1093/rheumatology/kex250.
［44］KHANNA D，FITZGERALD J D，KHANNA P P，et al．2012 American College of Rheumatology guidelines for management of gout.Part 1：systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia［J］．Arthritis Care Res（Hoboken），2012，64（10）：1431-1446．DOI：10.1002/acr.21772.

[1]	ZHU Danmeng, HUANG Yuying, LUO Tong'an, HE Changyuan, CHEN Rilan. Effect of Pricking-bloodletting Therapy Combined with Zhuang-medicine-thread Moxibustion on TLRs/MyD88 Signal Pathway in a Rat Model of Acute Gouty Arthritis [J]. Chinese General Practice, 2023, 26(20): 2525-2531.
[2]	WANG Junwei, LIN Lingjun, SONG Linling, CHENG Xiaocui, NIE Xiuling. Association between Serum Potassium and Metabolic-associated Fatty Liver Disease in Patients with Primary Gout [J]. Chinese General Practice, 2023, 26(12): 1479-1484.
[3]	Fanni XIAO, Yufeng QING, Quanbo ZHANG. Latest Advances in the Role of JAK/STAT Signaling Pathway in Autoimmune Rheumatic Diseases [J]. Chinese General Practice, 2022, 25(17): 2159-2164.
[4]	ZHANG Jinhuan，CHEN Yirong，LAN Kai，HU Liyu，YU Haibo. Clinical，Anti-hyperuricemic，and Pain-relief Effects of Five Acupuncture and Moxibustion Therapies in Acute Gouty Arthritis：a Network Meta-analysis　 [J]. Chinese General Practice, 2021, 24(8): 1001-1010.
[5]	WANG Xu，LUO Dongping，RU Yanhai，GUO Xiaokai，XU Jiayun. Interpretation of the Major Updates of Guidelines Regarding Hyperuricemia and Gout in Chronic Kidney Disease　 [J]. Chinese General Practice, 2021, 24(33): 4191-4195.
[6]	ZHANG Da，HUANG Zhifang，LI Xinlun，CUI Li. Comparative Interpretation of 2015—2020 Chinese and International Guidelines for the Diagnosis and Treatment of Gout　 [J]. Chinese General Practice, 2021, 24(33): 4196-4199.
[7]	LIU Min，MENG Juan. Interpretation of 2020 American College of Rheumatology Guideline for the Management of Gout from the Perspective of General Practitioners　 [J]. Chinese General Practice, 2021, 24(25): 3148-3153.
[8]	CHEN Shaohua，WANG Chinyun，WU Changgui，ZHAO Xiao，XU Hao，SHI Qi，LIANG Qianqian. Efficacy and Mechanism of Action of Danggui Niantong Decoction against Acute Gouty Arthritis in a Mouse Model：an Experimental Study　 [J]. Chinese General Practice, 2021, 24(24): 3116-3121.
[9]	JIANG Wencai，LI Yanzhuo，LI Jia，XU Lin. Gouty Arthritis Complicated with Erectile Dysfunction：a Case Report and Literature Review　 [J]. Chinese General Practice, 2021, 24(18): 2355-2358.
[10]	YANG Yanyu，LIU Taohong，WANG Dan，HUANG Yuqin，HE Xin，QING Yufeng，ZHANG Quanbo. Changes and Clinical Significance of Neutrophil/Lymphocyte Ratio of Intercritical Gout Patients　 [J]. Chinese General Practice, 2021, 24(14): 1820-1827.
[11]	DENG Kaifeng1，CHEN Rilan2，LI Shuzhen2，ZHU Shengwang1，YAN Jiaxing1，GAO Qianqian1，MA Yinglu1，ZHU Ying2*. Effect of Moxibustion with Ramie Threads Processed with the Zhuang Medicine on Serum Uric Acid and Joint Function in Patients with Gouty Arthritis: a Meta-analysis [J]. Chinese General Practice, 2020, 23(23): 2956-2963.
[12]	PANG Yubing，WANG Hui，ZHANG Minmin，WEI Hua，SHEN Weigan，ZHANG Yu. Factors associated with treat-to-target effect therapies for gout [J]. Chinese General Practice, 2020, 23(20): 2530-2535.
[13]	LIU Xiufang，LIU Li，ZHOU Yuqiu. Health Literacy in Young and Middle-aged Gout Patients in Northeastern China：a Qualitative Study　 [J]. Chinese General Practice, 2020, 23(15): 1916-1920.
[14]	ZHENG Qiyan，SUN Luying，ZHAO Qing，ZHANG Xiaoxiao，WANG Yahui，JIN Huanan，ZHANG Wen. Efficacy and Safety of Bushenxiezhuo Therapy versus Allopurinol in the Treatment of Gouty Nephropathy：a Meta-analysis [J]. Chinese General Practice, 2019, 22(8): 947-953.
[15]	LI Bohan，FANG Weigang，SHA Yue. Advances in Research on Factors Influencing Adherence to Urate-lowering Therapy in Patients with Gout　 [J]. Chinese General Practice, 2019, 22(7): 865-869.